|
HUE026260T2
(en)
|
2003-11-21 |
2016-06-28 |
Ucb Biopharma Sprl |
A method for treating multiple sclerosis by inhibiting IL-17 activity
|
|
EP1963368B3
(en)
*
|
2005-12-13 |
2020-06-10 |
Eli Lilly And Company |
Anti-il-17 antibodies
|
|
US7790163B2
(en)
|
2006-03-10 |
2010-09-07 |
Zymogenetics, Inc. |
Antibodies that bind both IL-17A and IL-17F and methods of using the same
|
|
EP1996622A2
(en)
|
2006-03-10 |
2008-12-03 |
Zymogenetics, Inc. |
Antibodies that bind both il-17a and il-17f and methods of using the same
|
|
US7910703B2
(en)
*
|
2006-03-10 |
2011-03-22 |
Zymogenetics, Inc. |
Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
|
|
TW200815469A
(en)
*
|
2006-06-23 |
2008-04-01 |
Astrazeneca Ab |
Compounds
|
|
GB0612928D0
(en)
*
|
2006-06-29 |
2006-08-09 |
Ucb Sa |
Biological products
|
|
EP2046835B1
(en)
|
2006-08-11 |
2011-10-26 |
Schering Corporation |
Antibodies to il-17a
|
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
|
RU2009137582A
(ru)
|
2007-03-12 |
2011-04-20 |
Эсбатек Аг (Ch) |
Инженерия и оптимизация одноцепочечных антител на основе последовательности
|
|
EP2164961B1
(en)
|
2007-06-25 |
2015-01-07 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Sequence based engineering and optimization of single chain antibodies
|
|
BRPI0813645A2
(pt)
*
|
2007-06-25 |
2014-12-30 |
Esbatech Alcon Biomed Res Unit |
Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
|
|
US20110300154A1
(en)
*
|
2007-08-21 |
2011-12-08 |
Children's Medical Center Corporation |
Treatment of airway hyperreactivity
|
|
WO2009082624A2
(en)
*
|
2007-12-10 |
2009-07-02 |
Zymogenetics, Inc. |
Antagonists of il-17a, il-17f, and il-23 and methods of using the same
|
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
|
RU2474588C2
(ru)
|
2008-05-05 |
2013-02-10 |
Новиммун Са |
Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
|
|
NZ591484A
(en)
*
|
2008-09-29 |
2012-09-28 |
Roche Glycart Ag |
Antibodies against human il 17 and uses thereof
|
|
SG2014006860A
(en)
*
|
2008-11-12 |
2014-05-29 |
Merck Sharp & Dohme |
ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
|
|
US20110223169A1
(en)
*
|
2008-11-26 |
2011-09-15 |
Stern Michael E |
Il-17 antibody inhibitor for treating dry eye
|
|
WO2010062857A1
(en)
|
2008-11-26 |
2010-06-03 |
Allergan, Inc. |
Klk-13 antibody inhibitor for treating dry eye
|
|
TWI541021B
(zh)
*
|
2009-03-05 |
2016-07-11 |
艾伯維有限公司 |
Ｉｌ－１７結合蛋白
|
|
CN102458437B
(zh)
|
2009-05-05 |
2015-06-10 |
诺维莫尼公司 |
抗il-17f抗体及其使用方法
|
|
EP2493506B1
(en)
|
2009-10-30 |
2019-04-10 |
Janssen Biotech, Inc. |
Il-17a antagonists
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
ES2993140T3
(en)
|
2010-04-02 |
2024-12-23 |
Amunix Pharmaceuticals Inc |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
US20110293629A1
(en)
*
|
2010-05-14 |
2011-12-01 |
Bastid Jeremy |
Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
|
|
NZ607615A
(en)
*
|
2010-08-05 |
2015-03-27 |
Anaptysbio Inc |
Antibodies directed against il-17
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
CN103154031A
(zh)
*
|
2010-10-08 |
2013-06-12 |
诺华有限公司 |
利用il-17拮抗剂治疗牛皮癣的方法
|
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
|
ME02734B
(me)
|
2011-01-14 |
2017-10-20 |
Ucb Biopharma Sprl |
Antitelo koje vezuje il-17a i il-17f
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
US9943594B2
(en)
|
2011-10-11 |
2018-04-17 |
Sanofi Biotechnology |
Methods for the treatment of rheumatoid arthritis
|
|
EP2783014A1
(en)
|
2011-11-21 |
2014-10-01 |
Novartis AG |
Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
|
|
EP2809660B1
(en)
|
2012-02-02 |
2016-01-20 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for modulating il-17
|
|
RS55417B1
(sr)
*
|
2012-03-07 |
2017-04-28 |
Lilly Co Eli |
Formulacija il-17 antitela
|
|
AR090626A1
(es)
*
|
2012-04-20 |
2014-11-26 |
Lilly Co Eli |
Anticuerpos anti-baff-anti-il-17 biespecificos
|
|
WO2013158821A2
(en)
|
2012-04-20 |
2013-10-24 |
Novartis Ag |
Methods of treating ankylosing spondylitis using il-17 antagonists
|
|
US8945553B2
(en)
*
|
2012-05-22 |
2015-02-03 |
Bristol-Myers Squibb Company |
Bispecific antibodies to IL-23 and IL-17A/F
|
|
WO2014001368A1
(en)
|
2012-06-25 |
2014-01-03 |
Orega Biotech |
Il-17 antagonist antibodies
|
|
WO2014066726A2
(en)
|
2012-10-26 |
2014-05-01 |
Ensemble Therapeutics Corporation |
Compounds for modulating il-17
|
|
MX2015006738A
(es)
|
2012-11-29 |
2015-08-05 |
Bayer Healthcare Llc |
Anticuerpos monoclonales humanizados contra la proteina c activada y sus usos.
|
|
LT2953969T
(lt)
*
|
2013-02-08 |
2019-12-10 |
Novartis Ag |
Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
|
|
TW201444867A
(zh)
|
2013-03-08 |
2014-12-01 |
Lilly Co Eli |
抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
|
|
WO2014155278A2
(en)
|
2013-03-26 |
2014-10-02 |
Novartis Ag |
Methods of treating autoimmune diseases using il-17 antagonists
|
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US20150004133A1
(en)
*
|
2013-06-07 |
2015-01-01 |
The Regents Of The University Of California |
Compositions And Methods For Treating Steatohepatitis, Liver Fibrosis, and Hepatocellular Carcinoma (HCC)
|
|
US9603882B2
(en)
|
2013-08-13 |
2017-03-28 |
Industrial Technology Research Institute |
Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
|
|
WO2015022656A1
(en)
|
2013-08-15 |
2015-02-19 |
Novartis Ag |
Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
|
|
HUE052184T2
(hu)
|
2013-11-18 |
2021-12-28 |
Shanghai hengrui pharmaceutical co ltd |
IL-17A kötõanyag és felhasználásai
|
|
US11421025B2
(en)
|
2013-12-27 |
2022-08-23 |
Osaka University |
Treatment of IL-17A diseases
|
|
US10519251B2
(en)
|
2013-12-30 |
2019-12-31 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
UA117608C2
(uk)
|
2014-02-21 |
2018-08-27 |
Дженентек, Інк. |
Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
|
|
RU2577228C2
(ru)
*
|
2014-03-14 |
2016-03-10 |
Закрытое Акционерное Общество "Биокад" |
Анти-il-17-антитела, способ их получения и способ применения
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
CN115957326A
(zh)
|
2014-09-10 |
2023-04-14 |
诺华股份有限公司 |
使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
EP3245224B1
(en)
|
2015-01-12 |
2020-07-15 |
Affibody AB |
Il-17a-binding polypeptides
|
|
JP2018506275A
(ja)
|
2015-01-28 |
2018-03-08 |
ジェネンテック， インコーポレイテッド |
多発性硬化症の遺伝子発現マーカー及び治療
|
|
CN106336459B
(zh)
*
|
2015-07-13 |
2020-12-08 |
三生国健药业（上海）股份有限公司 |
抗人白细胞介素-17a单克隆抗体、其制备方法和应用
|
|
EA201792527A1
(ru)
|
2015-07-16 |
2018-06-29 |
Эли Лилли Энд Компани |
Лечение зуда
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
WO2017087391A1
(en)
|
2015-11-17 |
2017-05-26 |
Bayer Healthcare, Llc |
Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
US11421028B2
(en)
|
2016-02-06 |
2022-08-23 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
CN107488227A
(zh)
*
|
2016-06-12 |
2017-12-19 |
三生国健药业（上海）股份有限公司 |
抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
|
|
WO2017221174A1
(en)
|
2016-06-22 |
2017-12-28 |
Novartis Ag |
Methods of treating vitiligo using interleukin-17 (il-17) antibodies
|
|
WO2018015880A1
(en)
|
2016-07-19 |
2018-01-25 |
Novartis Ag |
Methods of treating new-onset plaque type psoriasis using il-17 antagonists
|
|
ES2905917T3
(es)
*
|
2016-09-14 |
2022-04-12 |
Beijing Hanmi Pharmaceutical Co Ltd |
Anticuerpo que se une específicamente a IL-17A y fragmento funcional del mismo
|
|
JP2019505516A
(ja)
|
2016-11-28 |
2019-02-28 |
ノバルティス アーゲー |
インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
|
|
JP6995127B2
(ja)
|
2017-02-10 |
2022-02-04 |
ジェネンテック， インコーポレイテッド |
抗トリプターゼ抗体、その組成物、及びその使用
|
|
WO2018158741A1
(en)
|
2017-03-03 |
2018-09-07 |
Novartis Ag |
Psoriasis disease modification following long-term treatment with an il-17 antagonist
|
|
US10858427B2
(en)
|
2017-03-10 |
2020-12-08 |
Suzhou Kanova Biopharmaceutical Co., Ltd. |
Monoclonal antibody against both IL-17A and IL-17F and use of the same
|
|
WO2018170488A1
(en)
*
|
2017-03-17 |
2018-09-20 |
Gilead Sciences, Inc. |
Method of purifying an antibody
|
|
TW201842933A
(zh)
|
2017-05-05 |
2018-12-16 |
瑞士商諾華公司 |
使用il-17拮抗劑選擇性治療氣喘的方法
|
|
US11299540B2
(en)
|
2017-06-18 |
2022-04-12 |
Kindred Biosciences, Inc. |
IL17A antibodies and antagonists for veterinary use
|
|
WO2019027828A1
(en)
|
2017-08-04 |
2019-02-07 |
Eli Lilly And Company |
DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES
|
|
CN111032691A
(zh)
|
2017-08-23 |
2020-04-17 |
伊莱利利公司 |
生殖器银屑病的治疗
|
|
US20210179702A1
(en)
|
2017-11-02 |
2021-06-17 |
Novartis Ag |
Method of treating tendinopathy using interleukin-17 (il-17)
|
|
KR102048475B1
(ko)
*
|
2017-11-10 |
2019-11-26 |
주식회사 와이바이오로직스 |
IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
|
|
CN110914304B
(zh)
*
|
2017-11-10 |
2022-07-26 |
江苏恒瑞医药股份有限公司 |
Cd96抗体、其抗原结合片段及医药用途
|
|
US20200277369A1
(en)
|
2017-11-20 |
2020-09-03 |
Novartis Ag |
Method of treating hidradentitis suppurativa with il-17 antagonists
|
|
US20200371091A1
(en)
|
2017-11-30 |
2020-11-26 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
US11619832B2
(en)
|
2018-03-08 |
2023-04-04 |
Coopervision International Limited |
Identification of contact lens wearers predisposed to contact lens discomfort
|
|
EP3788079A4
(en)
|
2018-05-03 |
2022-12-21 |
Shanghai Epimab Biotherapeutics Co., Ltd. |
ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF
|
|
US12110323B2
(en)
|
2018-05-17 |
2024-10-08 |
Jiangsu Qyuns Therapeutics Co., Ltd. |
Anti-human interleukin 17A monoclonal antibody and application thereof
|
|
KR102870868B1
(ko)
|
2018-06-01 |
2025-10-15 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
GB201810327D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicycletx Ltd |
Peptide ligands for binding to IL-17
|
|
SG11202101674QA
(en)
|
2018-08-29 |
2021-03-30 |
Regeneron Pharma |
Methods and compositions for treating subjects having rheumatoid arthritis
|
|
EP3856772A1
(en)
|
2018-09-25 |
2021-08-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
|
CN111018974B
(zh)
*
|
2018-10-10 |
2022-04-01 |
东莞市朋志生物科技有限公司 |
一种抗人心肌肌钙蛋白i的重组抗体
|
|
GB201820316D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
CN109369806B
(zh)
*
|
2019-01-14 |
2019-04-19 |
迈威(上海)生物科技有限公司 |
苏金单抗制品中半胱氨酸化变异体的去除方法
|
|
EP3689907A1
(en)
|
2019-01-31 |
2020-08-05 |
Numab Therapeutics AG |
Antibodies targeting il-17a and methods of use thereof
|
|
EP4591879A3
(en)
|
2019-01-31 |
2025-10-22 |
Numab Therapeutics AG |
Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
|
|
MA54861A
(fr)
|
2019-01-31 |
2021-12-08 |
Regeneron Pharma |
Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
|
|
CN120241997A
(zh)
*
|
2019-02-18 |
2025-07-04 |
伊莱利利公司 |
治疗性抗体制剂
|
|
SG11202111742QA
(en)
|
2019-04-24 |
2021-11-29 |
Sanofi Biotechnology |
Methods of diagnosis and treatment of rheumatoid arthritis
|
|
KR102400401B1
(ko)
*
|
2019-05-22 |
2022-05-24 |
(주)셀인바이오 |
항염증 펩타이드 및 항염증 조성물
|
|
CA3142710A1
(en)
|
2019-06-04 |
2020-12-10 |
Sanofi Biotechnology |
Compositions and methods for treating pain in subjects with rheumatoid arthritis
|
|
ES3059248T3
(en)
|
2019-07-26 |
2026-03-19 |
Sinocelltech Ltd |
Humanized anti-il17a antibody and use thereof
|
|
US20220267432A1
(en)
|
2019-07-30 |
2022-08-25 |
Jiangsu Hengrui Medicine Co., Ltd. |
Method for treating autoimmune disease by il-17 antagonist
|
|
TW202126329A
(zh)
|
2019-09-20 |
2021-07-16 |
瑞士商諾華公司 |
使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法
|
|
CN114555792A
(zh)
|
2019-10-15 |
2022-05-27 |
伊莱利利公司 |
重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
|
|
AU2020386669A1
(en)
|
2019-11-19 |
2022-06-02 |
Novartis Ag |
Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists
|
|
CA3162052A1
(en)
|
2019-12-06 |
2021-06-10 |
Novartis Ag |
Methods of treating lichen planus using interleukin-17 (il-17) antagonists
|
|
GB201918557D0
(en)
|
2019-12-16 |
2020-01-29 |
Bicycle Tx Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
WO2021123767A1
(en)
|
2019-12-16 |
2021-06-24 |
Bicycletx Limited |
Bicyclic peptide ligands specific for il-17
|
|
GB201918558D0
(en)
|
2019-12-16 |
2020-01-29 |
Bicycle Tx Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
GB201918559D0
(en)
|
2019-12-16 |
2020-01-29 |
Bicycle Tx Ltd |
Bicyclic peptide ligands specific for IL-17
|
|
GB201919062D0
(en)
*
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
|
CA3180084A1
(en)
|
2020-05-27 |
2021-12-02 |
Barrie Phillip MARTIN |
Il-17a modulators
|
|
EP4157828A1
(en)
|
2020-05-27 |
2023-04-05 |
Sanofi |
Il-17a modulators
|
|
CN115812079A
(zh)
|
2020-06-23 |
2023-03-17 |
诺华股份有限公司 |
使用白细胞介素-17(il-17)拮抗剂治疗甲状腺眼病和格雷夫斯眼眶病的方法
|
|
CA3199095A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
CN115746132B
(zh)
*
|
2021-09-03 |
2023-09-08 |
三优生物医药(上海)有限公司 |
抗il-17a抗体及其用途
|
|
IT202100023816A1
(it)
*
|
2021-09-16 |
2023-03-16 |
Takis S R L |
Anticorpo contro SARS-CoV-2 e suoi usi in campo medico.
|
|
CN113896793B
(zh)
*
|
2021-09-30 |
2023-05-26 |
港科鹏禾生物(苏州)有限公司 |
一种抗人il-17rc的单克隆抗体及其应用
|
|
IL317086A
(en)
|
2022-05-16 |
2025-01-01 |
Novartis Ag |
Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
|
|
IL316872A
(en)
|
2022-05-18 |
2025-01-01 |
Novartis Ag |
Methods for selective treatment of tendinopathy using interleukin-17 (IL-17) antagonists
|
|
CN120530100A
(zh)
|
2022-12-09 |
2025-08-22 |
赛诺菲 |
治疗性化合物
|
|
WO2025083549A1
(en)
|
2023-10-16 |
2025-04-24 |
Sun Pharma Advanced Research Company Limited |
Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
|
|
WO2025104230A1
(en)
|
2023-11-17 |
2025-05-22 |
Sanofi |
Benzoxazoles as modulators of il-17a
|
|
WO2025248073A1
(en)
|
2024-05-30 |
2025-12-04 |
Sanofi |
Therapeutic compounds
|
|
KR20250179689A
(ko)
|
2024-06-20 |
2025-12-30 |
(주)셀트리온 |
안정한 약제학적 제제
|
|
CN120249218B
(zh)
*
|
2024-10-15 |
2026-03-20 |
武汉纺织大学 |
一种分泌抗微纳塑料广谱性单克隆抗体的杂交瘤细胞株及其应用
|